NCT07368361 Th Study Wants to Compare the Best Technique for Sinus Operation in CRSWNP
| NCT ID | NCT07368361 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kafrelsheikh University |
| Condition | CRSWNP |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-01-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial aims to compare the efficacy and safety of reboot surgery versus conventional full house FESS in patients with refractory CRSwNP, focusing on: 1\. Primary Outcome: * Compare 24-month recurrence rates (defined as endoscopic polyp score ≥2) 2. Secondary Outcomes: * Recurrence-free survival (time to first recurrence), Quality of life improvement (SNOT-22 scores), Reduction in systemic corticosteroid use, Complication rates (synechiae, bleeding, infection) and Cost-effectiveness of each approach
Eligibility Criteria
Inclusion Criteria:Patients above the age of 18 years presenting with recurrent refractory CRSwNP (failed ≥1 biologic/prior FESS), Type-2 endotype confirmation (blood/tissue eosinophilia, IgE ≥100 IU/mL), Lund-Mackay CT score ≥10 will be included in the study. Exclusion Criteria: eosinophilic granulomatosis with polyangiitis (EGPA) or severe systemic diseases (except controlled asthma or NSAID-exacerbated respiratory disease), neoplasms, vasoconstrictor abuse (e.g., oxymetazoline dependence), unilateral nasal inflammatory disease, bilateral inflammatory disease without polyps, or treatment with monoclonal antibodies in the past 12 months, Patients younger than 18 years of age and patients are unfit for general anesthesia.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07368361 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying CRSWNP. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07368361 currently recruiting?
Yes, NCT07368361 is actively recruiting participants. Contact the research team at amrshady00@gmail.com for enrollment information.
Where is the NCT07368361 trial being conducted?
This trial is being conducted at Egypt, Canada.
Who is sponsoring the NCT07368361 clinical trial?
NCT07368361 is sponsored by Kafrelsheikh University. The trial plans to enroll 40 participants.